Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393497 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment
A Phase 1 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00393497 is a Phase 1 study that has completed, run by Indiana University. The registered enrollment target is 11 participants.
The verdict
NCT00393497, a Phase 1 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of bevacizumab in women with lymphedema as a result of previous treatment for breast cancer.
Interventions
- DRUG bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00393497
The ClinicalTrials.gov registry entry for NCT00393497 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bevacizumab is the first listed.
NCT00393497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00393497 about?
NCT00393497 is a clinical study titled "A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment". The purpose of this study is to evaluate the effectiveness of bevacizumab in women with lymphedema as a result of previous treatment for breast cancer.
What is the current status of trial NCT00393497?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2007-04. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00393497?
The interventions under investigation include: bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00393497?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.